• 1
    O'Neill LA, Bowie AG. The family of five: TIR-domain containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007; 7: 35364.
  • 2
    Kumar H, Kawai T, Akira S. Pathogen recognition in the innate immune response. Biochem J 2009; 420: 116.
  • 3
    Beutler B. Interferences, questions and possibilities in Toll-like receptor signaling. Nature 2004; 430: 25763.
  • 4
    Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004; 5: 7307.
  • 5
    Beutler B. Microbe sensing, positive feedback loops, and the pathogenesis of inflammatory diseases. Immunol Rev 2009; 227: 24863.
  • 6
    Schmidt AT, Schwerd W, Hamm JC, Hellmuth S, Cui M, Wenzel FS, et al. 59-triphosphate RNA requires base-paired structures to activate antiviral signalling via RIG-I. Proc Natl Acad Sci U S A 2009; 106: 1206772.
  • 7
    Schlee M, Roth A, Hornung V, Hagmann CA, Wimmenauer V, Barchet W, et al. Recognition of 59-triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity 2009; 31: 2534.
  • 8
    Pichlmair A, Schulz O, Tan CP, Rehwinkel J, Kato H, Takeuchi O, et al. Activation of MDA5 requires higher-order RNA structures generated during virus infection. J Virol 2009; 83: 107619.
  • 9
    Ranjith-Kumar CT, Murali A, Dong W, Srisathiyanarayanan D, Vaughan R, Ortiz-Alcantara J, et al. Agonist and antagonist recognition by RIG-I, a cytoplasm innate immunity receptor. J Biol Cell 2009; 284: 115565.
  • 10
    Wilkins C, Gale M Jr. Recognition of viruses by cytoplasmic sensors. Curr Opin Immunol 2009; 22: 17.
  • 11
    Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003; 423: 35661.
  • 12
    Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 2010; 233: 23355.
  • 13
    Toussirot E, Roudier J. Pathophysiological links between rheumatoid arthritis and the Epstein-Barr virus: an update. Joint Bone Spine 2007; 74: 41826.
  • 14
    Brentano F, Schorr O, Gay RE, Gay S, Kyburz D. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum 2005; 52: 265665.
  • 15
    Roelofs MF, Boelens WC, Joosten LA, Abdollahi-Roodsaz S, Geurts J, Wunderink LU, et al. Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis. J Immunol 2006; 176: 70217.
  • 16
    Seibl R, Birchler T, Loeliger S, Hossle JP, Gay RE, Saurenmann T, et al. Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium. Am J Pathol 2003; 162: 12217.
  • 17
    Radstake TR, Roelofs MF, Jenniskens YM, Oppers-Walgreen B, van Riel PL, Barrera P, et al. Expression of Toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-γ. Arthritis Rheum 2004; 50: 385665.
  • 18
    Roelofs MF, Joosten LA, Abdollahi-Roodsaz S, van Lieshout AW, Sprong T, van den Hoogen FH, et al. The expression of Toll-like receptors 3 and 7 in rheumatoid synovium is increased and costimulation of Toll-like receptors 3, 4, 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum 2005; 52: 231322.
  • 19
    Gutierrez-Canas I, Juarranz Y, Santiago B, Arranz A, Martinez C, Galindo M, et al. VIP down-regulates TLR4 expression and TLR4-mediated chemokine production in human rheumatoid synovial fibroblasts. Rheumatology (Oxford) 2006; 45: 52732.
  • 20
    Arranz A, Gutierrez Canas I, Carrion M, Juarranz Y, Pablos JL, Martinez C, et al. VIP reverses the expression profiling of TLR4-stimulated signalling pathway in rheumatoid arthritis synovial fibroblasts. Mol Immunol 2008; 45: 306573.
  • 21
    Abad C, Martinez C, Juarranz MG, Arranz A, Leceta J, Delgado M, et al. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid model of Crohn's disease. Gastroenterology 2003; 124: 96171.
  • 22
    Delgado M, Pozo D, Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 2004; 56: 24990.
  • 23
    Li H, Mei Y, Wang Y, Xu L. Vasoactive intestinal peptide suppressed experimental autoimmune encephalomyelitis by inhibiting T helper 1 responses. J Clin Immunol 2006; 26: 4307.
  • 24
    Lodde BM, Mishiba F, Wang J, Cotrim AP, Afiore S, Tak PP, et al. Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjögren's syndrome. Ann Rheum Dis 2006; 65: 195200.
  • 25
    Said SI, Hamidi SA, Dickman KG, Szema AM, Lyubsky S, Lin RZ, et al. Moderate pulmonary arterial hypertension in the male mice lacking the vasoactive intestinal peptide gene. Circulation 2007; 115: 12608.
  • 26
    Jimeno R, Gomariz RP, Gutierrez-Canas I, Martinez C, Juarranz Y, Leceta J. New insights into the role of VIP on the ratio of T-cell subsets during the development of autoimmune diabetes. Immunol Cell Biol 2010; 88: 73445.
  • 27
    Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 2001; 7: 5638.
  • 28
    Juarranz MG, Santiago B, Torroba M, Gutierrez-Canas I, Palao G, Galindo M, et al. Vasoactive intestinal peptide modulates proinflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells. Rheumatology (Oxford) 2004; 43: 41622.
  • 29
    Juarranz Y, Gutierrez-Canas I, Arranz A, Martinez C, Abad C, Leceta J, et al. VIP decreases TLR4 expression induced by LPS and TNFα treatment in human synovial fibroblasts. Ann N Y Acad Sci 2006; 1070: 35964.
  • 30
    Gutierrez-Canas I, Juarranz Y, Santiago B, Martinez C, Gomariz RP, Pablos JL, et al. Immunoregulatory properties of vasoactive intestinal peptide in human T cell subsets: implications for rheumatoid arthritis. Brain Behav Immun 2008; 22: 3127.
  • 31
    Juarranz Y, Gutierrez-Canas I, Santiago B, Carrion M, Pablos JL, Gomariz RP. Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts. Arthritis Rheum 2008; 58: 108695.
  • 32
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 33
    Pablos JL, Santiago B, Galindo M, Torres C, Brehmer MT, Blanco FJ, et al. Synoviocyte-derived CXCL12 is displayed on endothelium and induces angiogenesis in rheumatoid arthritis. J Immunol 2003; 170: 214752.
  • 34
    Birmachu W, Gleason RM, Bulbulian BJ, Riter CL, Vasilakos JP, Lipson KE, et al. Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR7 agonists. BMC Immunology 2007; 8: 26.
  • 35
    Brentano F, Kyburz D, Gay S. Toll-like receptors and rheumatoid arthritis. In: McCoyCE, O'NeillLA, editors. Methods in molecular immunology: Toll-like receptors. Vol. 517. Secaucus (NJ): Springer; 2009. p. 32943.
  • 36
    Imaizumi T, Arikawa T, Sato T, Uesato R, Matsumiya T, Yoshida H, et al. Involvement of retinoic acid-inducible gene-I in inflammation of rheumatoid fibroblast-like synoviocytes. Clin Exp Immunol 2008; 153: 2404.
  • 37
    Ospelt C, Brentano F, Rengel Y, Stanczyk J, Kolling C, Tak PP, et al. Overexpression of Toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: Toll-like receptor expression in early and longstanding arthritis. Arthritis Rheum 2008; 58: 368492.
  • 38
    Barral PM, Sarkar D, Su ZZ, Barber GN, DeSalle R, Racaniello VR, et al. Functions of the cytoplasmic RNA sensors RIG-I and MDA5: key regulators of innate immunity. Pharmacol Ther 2009; 124: 21934.
  • 39
    Roelofs MF, Wenink MH, Brentano F, Abdollahi-Roodsaz S, Oppers-Walgreen B, Barrera P. Type I interferons might form the link between Toll-like receptor (TLR) 3/7 and TLR4 mediated synovial inflammation in rheumatoid arthritis (RA). Ann Rheum Dis 2008; 68: 148693.
  • 40
    Panne D, Maniatis T, Harrison SC. An atomic model of the interferon-β enhanceosome. Cell 2007; 129: 111123.
  • 41
    Sweeney SE, Kimbler TB, Firestein GS. Synoviocyte innate immune responses: II. Pivotal role of regulatory factor 3. J Immunol 2010; 184: 71628.
  • 42
    Zare F, Bokarewa M, Nenonen N, Bergstrom T, Alexopoulu L, Flavell RA. Arthritogenic properties of double-stranded (viral) RNA. J Immunol 2004; 172: 565663.
  • 43
    Gomariz RP, Gutierrez-Canas I, Arranz A, Carrion M, Juarranz Y, Leceta J, et al. Peptides targeting Toll-like receptor signalling pathways for novel immune therapeutics. Curr Pharm Design 2010; 16: 106380.
  • 44
    Van Holten J, Pavelka K, Vencovsky J, Stahl H, Rozman B, Genovese M, et al. A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon-β in the treatment of patients with active rheumatoid arthritis. Ann Rheum Dis 2005; 64: 649.
  • 45
    Herrera JL, Gonzalez-Rey E, Fernandez-Montesinos R, Quintana FJ, Najmanovich R, Pozo D. Toll-like receptors stimulation differentially regulates vasoactive intestinal peptide type 2 receptor in macrophages. Cell Mol Med 2009; 13: 320917.
  • 46
    Lee H, Park K, Kim JS, Lee SJ. Vasoactive intestinal peptide inhibits Toll-like receptor 3-induced nitric oxide production in Schwann cells and subsequent sensory neuronal cell death in vitro. J Neuros Res 2009; 87: 1718.
  • 47
    Sawada S, Takei M, Inomata H, Nozaki T, Shimiraiwa H. What is after cytokine-blocking therapy? A novel therapeutic target-synovial Epstein-Barr virus for rheumatoid arthritis. Immunol Rev 2007; 6: 12630.
  • 48
    Pratesi F, Tommasi C, Anzilotti C, Chimenti D, Migliorini P. Deiminated Epstein-Barr virus nuclear antigen 1 is a target of anti–citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum 2006; 54: 73341.
  • 49
    Galeazzi M, Morozzi G, Piccini M, Chen J, Bellisai F, Fineschi S, et al. Dosage and characterization of circulating DNA: present usage and possible applications in systemic autoimmune disorders. Autoimmun Rev 2003; 2: 505.
  • 50
    Magnusson M, Zare F, Tarkowski A. Requirement of type I interferon signalling for arthritis triggered by double-stranded RNA. Arthritis Rheum 2006; 54: 14857.